Cure CMD Grants

Cure CMD Research Grant Goals

Cure CMD research goals reflect our mission to bring research, treatments and in the future, a cure for the congenital muscular dystrophies.

  1. Identify new therapeutic targets in the CMDs
  2. Identify small molecule compounds that work at these therapeutic target sites with priority towards drugs with existing pediatric FDA approval
  3. Facilitate the drug development process to ensure that each positive drug identification with promising preliminary data can be brought rapidly to preclinical trials and subsequent treatment trials
  4. Support and endorse clinical research, infrastructure and biomarker discovery required to launch effective and efficient clinical trials in rare disease
  5. Advance drug discovery with a diverse treatment pipeline
  6. Support new scientific investigators with innovative ideas and a commitment to CMD research

Updated Annual Deadline: January 15, 2015

Cure CMD will delay the 2014 grant cycle until January 15, 2015, with funding announcements by April 15, 2015.

Grant Application
Grant Policies
Grant Guidelines

Cure CMD funds two types of grants.  Please use the same application to apply for either type of grant.

Cure CMD Short Term Research Grant: Cure CMD provides a short-range or “seed” grant (usually $30,000 per year for 1-2 years, direct costs only) to attract new investigators to the CMD field and assist existing investigators to support early phases of their research. The short-range grant focus is to collect preliminary data and test initial hypotheses. The short-range grant goal is to translate successful preliminary research to either second tier Cure CMD midrange grants (R-21 type) or third tier, long range (R-01 grants, 2-5 years) from outside funding sources, such as the National Institutes of Health. Annual RFA deadline, Sept 15th. Grant application above. On the first page of the Cure CMD grant application, specify CMD  Short Term CMD Research Grant.

Cure CMD Midrange grant: Cure CMD provides a 1-2 year midrange grant targeting more mature research, (usually $50,000 per year for 1-2 years, direct costs only). This grant submission requires evidence of preliminary data supporting hypothesis driven research. Funding support for these two tiered research grants comes from Cure CMD. Grant application above. On the first page of the Cure CMD grant application, specify Midrange Grant.

2013 Cure CMD Grant Recipients:

  • Antoine Muchir, PhD.  LMNA Cardiac Discovery: Developing Longitudinal Models in H222P and DELK32 mouse models. (1 year funding)
  • Francesco Muntoni, MD. Expression analysis of miRNAs in serum and muscle samples in LAMA2-deficient Congenital Muscular Dystrophy and their implication as biomarkers. (1 year funding)
  • Sebahattin Cirak, PhD, MD. Deciphering the biochemical function of ISPD and drug discovery (chemical chaperones) for ISPD-related muscular dystrophy. (2 year funding)
  • Sweta Girgenrath, PhD. Inhibition of Angiotensin II signaling in Congenital Muscular Dystrophy Type1A (MDC1A) (2 year funding)
  • Russ Butterfield, PhD. Transcriptome profiling for identification of biomarkers in congenital muscular dystrophy (1 year funding)

2012 Cure CMD Grant Recipients:

  • Valerie Allamand, PhD, In vitro and in vivo assessment of PTC suppression strategies for COLVI- myopathies (2 year funding)
  • Alan Beggs, PhD, Zebrafish Models for Drug Discovery in SEPN1, RYR1 and TTN Myopathies (1 year Funding)
  • Glenn Morris and Susan Brown, PhD. Generation and characterization of antibodies to alpha dystroglycan. (Co-Funded with LGMD2I Fund)
  • Dean Burkin, PhD, MDC1A Global Transcriptome, Cell Signaling and Human Laminin Protein Preclinical and Pharmacokinetic/Pharmacodynamics Study (2 year funding)
  • Olga Igoucheva, PhD. Therapeutic Potential of Adult Stem Cells in Congenital Muscular Dystrophies (2 year funding)
  • David Sassoon, PhD Dissecting the role of PWI/Peg3 in the stress response of resident muscle stem cells in laminin alpha 2- deficient muscular dystrophy (1 year funding)
  • Xiao Xiao, PhD, Development of AAV Miniagrin for FKRP-MD Murine and IPS work (1 year funding) (Cofunded with LGMD2I Fund)
  • Kanneboyina Nagaraju, DVM, Characterization of FKRP-MD Mouse Model (co-funding with LGMD2I Fund) (1 year funding)
  • Cellular Dynamics Inc. Development of 2 FKRP IPS and 3 LMNA IPS lines. (Co-funding with LGMD2I Fund)

2011 Cure CMD Grant Recipients:

  • Dr. Gisele Bonne, PhD, INSERM, France, “Novel Trans-splicing Mechanism for LMNA related dystrophy”
  • Dr. James Dowling, MD, PhD, University of Michigan, “Zebrafish Models of CMD”
  • Dr. William Cruikshank, PhD, Boston University, “Evaluating the Respiratory System in a CMD Animal Model (Dyw)”

2010 Cure CMD Short Term Research Grant Recipients:

  • Dr. Susan Brown, Royal Veterinary College, United Kingdom, “Validation of an Animal Model for Therapeutic Testing In the Dystroglycanopathies” (2 year funding)
  • Dr. Kanneboyina Nagaraju, CNMC, USA, “Validation of Omigapil in LAMA2 Related CMD Animal Model and Endpoint Validation in Col6KI Model” (supplemental funding to CTSA)

2010 Cure CMD Midrange Research Grant Recipients:

  • Dr. Valerie Allamand, INSERM, Institute de Myologie, France, “PTC Suppression in a Novel Model of Col6 Myopathy” (2 year funding)
  • Drs. Olga Igoucheva and Mon-li Chu, Thomas Jefferson University, USA, “Therapeutic Potential of Adult Stem Cells for Collagen 6 Muscular Dystrophy” (2 year funding)

2010 SAM CMD Translational Research Grant Recipient:

  • Dr. Sweta Girgenrath, Boston University, USA, “To Evaluate the Efficacy of RAP-031 Treatment of Dystrophic, Inflammatory and Regenerative Deficiencies in Merosin Deficient Congenital Muscular Dystrophy Animal Model” (1 year funding)

2009 Cure CMD Short Term Research Grant Recipient:

  • Dr. Ana Ferreiro, INSERM, France, “Pharmacological Therapy of SEPN1 Related Myopathy: From Ex Vivo Studies to the First Clinical Trial” (1 year funding)

2009 SAM CMD Translational Award Recipients:

  • Dr. Denis Guttridge, Ohio State University Medical Center, “Elucidating NF-kappa B Function in Congenital Muscular Dystrophy” (2 year funding)
  • Dr. Sweta Girgenrath, Boston University, USA, “Triggering Regeneration and Tackling Degeneration: A Comprehensive Approach for Treating Muscular Dystrophy”
  • Dr. James Collins, Cincinnati Childrens Hospital Medical Center, USA, “Transciptomic and Proteomic Profiling in Blood of Patients with Laminin Alpha 2 Deficiency; A Biomarker Pilot Study” (1 year funding)
  • Dr. Dean Burkin, University of Nevada, USA, “Laminin 111 Protein Therapy for Merosin Deficient Congenital Muscular Dystrophy” (1 year funding)
  • Congenital Muscular Dystrophy

    A group of diseases causing muscle weakness at birth. Several defined genetic mutations cause muscles to break down faster than they can repair or grow. A child with CMD may have various neurological or physical impairments. Some children never gain the ability to walk, while others lose the ability as they grow older. Learn more...

  • Register Now!